Oxford BioDynamics Plc has posted increased revenues while losses narrowed slightly in the year ended 30th September 2025.

The precision clinical diagnostics company, behind the EpiSwitch 3D genomics platform, said linical test revenue was 2.7x highe than the prior year at £1.1m (FY24: £400,000).

Operating loss was £11.1m, down from £12.9m in FY24.

Iain Ross, who joined as chairman in January, said: “This has been an exciting period of renewal, and it is encouraging to see revenue-generating and cost-saving initiatives starting to deliver.”